Stroke RSS

Filtered By:
Source: JAHA:Journal of the American Heart Association
Drug: Cilostazol

Filter By:
Specialty
Source
Condition
Cancer
Infectious Disease
Drug
Training
Management
Procedure
Therapy
Vaccine
Nutrition
Country

This page shows you your search results in order of date.

Order by Relevance | Date

Total 1 results found since Jan 2013.

Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis Stroke
Conclusions Long-term monotherapy was a better choice than long-term dual therapy, and cilostazol had the best risk–benefit profile for long-term secondary prevention after stroke or transient ischemic attack. More randomized controlled trials in non–East Asian patients are needed to determine whether long-term use of cilostazol is the best option for the prevention of recurrent stroke.
Source: JAHA:Journal of the American Heart Association - August 24, 2015 Category: Cardiology Authors: Xie, W., Zheng, F., Zhong, B., Song, X. Tags: Stroke Source Type: research